NCT04732650 is a clinical trial in Eisenmenger Complex, sponsored by Samsung Medical Center.

Who is sponsoring NCT04732650?

NCT04732650 is sponsored by Samsung Medical Center.

What condition does NCT04732650 study?

NCT04732650 studies Eisenmenger Complex.

Is NCT04732650 still recruiting?

NCT04732650 is currently status unknown. Last updated 1 February 2021.

Last reviewed 2021-02-01 · How we verify

NCT04732650

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome

Status unknown Last updated 1 February 2021

What this trial tests

trial in Eisenmenger Complex in 40 participants. Status unknown.

Timeline

4 February 2021

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Samsung Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	4 February 2021
Primary completion	31 December 2023
Estimated completion	31 December 2024

Conditions studied

Eisenmenger Complex — all drugs for Eisenmenger Complex →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Eisenmenger Complex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04732650 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 1 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04732650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing